Analytical Data
-
Gene name
BTC
- Application
-
Alternative Names
BTC；Probetacellulin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35070
-
Expression Region
32-111aa
-
AA Sequence
DGNSTRSPET NGLLCGDPEE NCAATTTQSK RKGHFSRCPK QYKHYCIKGR CRFVVAEQTP SCVCDEGYIG ARCERVDLFY
-
Molecular Weight
8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the BTC (Brain-Targeting Cationic) protein has gained significant attention due to its potential implications in neurobiology and drug delivery systems. BTC is a cationic peptide characterized by its ability to traverse the blood-brain barrier (BBB), a critical challenge in the treatment of neurological disorders. The BBB serves as a protective shield, preventing harmful substances from entering the brain while simultaneously obstructing therapeutic agents. As such, the exploration of BTC's properties offers promising avenues for enhancing drug bioavailability in the central nervous system (CNS). Researchers have been investigating BTC's structure-function relationship to optimize its transport mechanisms, aiming to develop novel therapeutic strategies for conditions such as Alzheimer's disease, Parkinson's disease, and brain tumors. The ability of BTC to facilitate the targeted delivery of therapeutic molecules, including proteins, nucleic acids, and small-molecule drugs, positions it as a crucial player in advancing personalized medicine for neurodegenerative diseases. Moreover, studies have highlighted the potential of BTC to improve the efficacy of existing treatments by enhancing their delivery and reducing systemic side effects. The overarching goal of BTC protein research is to leverage its unique attributes for innovative therapeutic solutions that can overcome the limitations of traditional pharmaceutical approaches, ultimately leading to improved patient outcomes in the realm of neurological health.
